Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 816 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: AbbVie Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

NCT04169373
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
41
States / cities
Flagstaff, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Active, not recruiting Phase 2 Interventional

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

NCT06522386
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Pirtobrutinib, Rituximab, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

NCT05940402
View directory record Official record
Conditions
Renal Impairment
Interventions
Emraclidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Tustin, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 22, 2026, 11:22 AM EDT
Active, not recruiting Phase 2 Interventional

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT04514653
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Local Steroid, Topical Steroid, ABBV-RGX-314 Dose 4
Biological · Genetic · Drug
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 1 Interventional

RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER

NCT02029729
View directory record Official record
Conditions
Metastatic or Incurable Non-small Cell Lung Cancer, Relapsed, Refractory Melanoma
Interventions
omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 22, 2026, 11:22 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

NCT07807956
View directory record Official record
Conditions
Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Cancer
Interventions
ABBV-253
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Grand Rapids, Michigan • Huntersville, North Carolina • Irving, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

NCT00548925
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-894, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Spring Valley, California • Walnut Creek, California • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

NCT02264990
View directory record Official record
Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
Paclitaxel, Carboplatin, Cisplatin, Veliparib, Pemetrexed
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
25
States / cities
Huntsville, Alabama • Mobile, Alabama • Springdale, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 22, 2026, 11:22 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

NCT03844815
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Decitabine, Venetoclax
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Recruiting Phase 2 Interventional

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

NCT07097363
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, Epcoritamab, Etoposide, Fludeoxyglucose F-18, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Rituximab
Procedure · Drug · Biological + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Terminated Phase 1 Interventional

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

NCT04274907
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cancer
Interventions
Venetoclax, Pembrolizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • Santa Rosa, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT01306617
View directory record Official record
Conditions
Chronic Hepatitis C Infection, Hepatitis C, Hepatitis C Virus
Interventions
ABT-450, ABT-333, ribavirin, ritonavir
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 1 Interventional

A Study of ABT-165 in Subjects With Solid Tumors

NCT01946074
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
paclitaxel, FOLFIRI, ABT-165, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

NCT01506609
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Placebo, Veliparib, Carboplatin, Temozolomide, Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
34
States / cities
Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 2 Interventional Results available

Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy

NCT01038609
View directory record Official record
Conditions
Pain
Interventions
Hydrocodone/Acetaminophen Extended Release, Acetaminophen, Morphine Extended Release, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Peoria, Arizona • Austin, Texas • San Marcos, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT04195698
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
33
States / cities
Little Rock, Arkansas • Fountain Valley, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 22, 2026, 11:22 AM EDT
Recruiting Phase 2 Interventional

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

NCT06510309
View directory record Official record
Conditions
Lymphoma, Marginal Zone Lymphoma, MZL
Interventions
Venetoclax, Rituximab
Drug
Lead sponsor
Gottfried von Keudell, MD PhD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT01594229
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
ABT-199, Rituximab, Bendamustine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
8
States / cities
La Jolla, California • Los Angeles, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 22, 2026, 11:22 AM EDT
Terminated Phase 1 Interventional

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer

NCT02819999
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Rovalpituzumab Tesirine, Cisplatin, Etoposide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Aurora, Colorado • Denver, Colorado • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

NCT03104400
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Adalimumab, Upadacitinib, Placebo to Upadacitinib, Placebo to Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
114
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 22, 2026, 11:22 AM EDT
Recruiting Phase 3 Interventional

Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

NCT06575192
View directory record Official record
Conditions
Breast Reconstruction
Interventions
ARTIA Reconstructive Tissue Matrix
Device
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

NCT03518034
View directory record Official record
Conditions
Hypogonadism, Cardiovascular Diseases
Interventions
AndroGel®, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
5,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
379
States / cities
Alabaster, Alabama • Birmingham, Alabama • Decatur, Alabama + 262 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 22, 2026, 11:22 AM EDT
Completed Phase 4 Interventional Results available

Study of Oral Treatments for Hepatitis C

NCT02786537
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir), Ribavirin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
1,275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
38
States / cities
Little Rock, Arkansas • Palo Alto, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 22, 2026, 11:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

NCT06365853
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
Interventions
Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 11:22 AM EDT